Literature DB >> 18166803

High-dose chemotherapy and autologous stem-cell transplantation without consolidating radiotherapy as first-line treatment for primary lymphoma of the central nervous system.

Gerald Illerhaus, Fabian Müller, Friedrich Feuerhake, Arnd-Oliver Schäfer, Christoph Ostertag, Jürgen Finke.   

Abstract

Thirteen patients (age 38-67 years) with primary lymphoma of the central nervous system (CNS) were treated with methotrexate and cytarabine/thiotepa induction-chemotherapy followed by high-dose carmustine/thiotepa and autologous stem-cell transplantation. Radiotherapy was restricted to patients who did not respond completely to chemotherapy. With a median follow up of 25 months, 3-year DFS and OS was 77%.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18166803     DOI: 10.3324/haematol.11771

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  53 in total

1.  Flows and flaws in primary central nervous system lymphoma.

Authors:  Andrés J M Ferreri; Gerald Illerhaus; Emanuele Zucca; Franco Cavalli
Journal:  Nat Rev Clin Oncol       Date:  2010-08       Impact factor: 66.675

2.  Primary CNS lymphoma.

Authors:  Uwe Schlegel
Journal:  Ther Adv Neurol Disord       Date:  2009-03       Impact factor: 6.570

Review 3.  Primary central nervous system lymphoma: implication of high-dose chemotherapy followed by auto-SCT.

Authors:  N Reddy; B N Savani
Journal:  Bone Marrow Transplant       Date:  2011-10-17       Impact factor: 5.483

Review 4.  Pharmacotherapy for primary CNS lymphoma: progress beyond methotrexate?

Authors:  Jerome J Graber; Antonio Omuro
Journal:  CNS Drugs       Date:  2011-06-01       Impact factor: 5.749

5.  Monotherapy with methotrexate for primary central nervous lymphoma has single agent activity in the absence of radiotherapy: a single institution cohort.

Authors:  Julien Cobert; Ephraim Hochberg; Nina Woldenberg; Fred Hochberg
Journal:  J Neurooncol       Date:  2009-12-18       Impact factor: 4.130

Review 6.  New approaches in primary central nervous system lymphoma.

Authors:  Eleanor Fraser; Katherine Gruenberg; James L Rubenstein
Journal:  Chin Clin Oncol       Date:  2015-03

7.  Salvage therapy with bendamustine for methotrexate refractory recurrent primary CNS lymphoma: a retrospective case series.

Authors:  Marc C Chamberlain
Journal:  J Neurooncol       Date:  2014-03-01       Impact factor: 4.130

8.  Promising treatment results with blood brain barrier disruption (BBBD) based immunochemotherapy combined with autologous stem cell transplantation (ASCT) in patients with primary central nervous system lymphoma (PCNSL).

Authors:  Hanne Kuitunen; Susanna Tokola; Topi Siniluoto; Matti Isokangas; Eila Sonkajärvi; Seppo Alahuhta; Taina Turpeenniemi-Hujanen; Esa Jantunen; Tapio Nousiainen; Kaija Vasala; Outi Kuittinen
Journal:  J Neurooncol       Date:  2016-10-17       Impact factor: 4.130

9.  Rituximab, methotrexate, procarbazine, vincristine and intensified cytarabine consolidation for primary central nervous system lymphoma (PCNSL) in the elderly: a LOC network study.

Authors:  Caroline Houillier; Hervé Ghesquières; Cécile Chabrot; Carole Soussain; Guido Ahle; Sylvain Choquet; Emmanuelle Nicolas-Virelizier; Jacques-Olivier Bay; Jacques Vargaftig; Claude Gaultier; Valérie Touitou; Nadine Martin-Duverneuil; Nathalie Cassoux; Magali Le Garff-Tavernier; Myrto Costopoulos; Pierre Faurie; Khê Hoang-Xuan
Journal:  J Neurooncol       Date:  2017-04-21       Impact factor: 4.130

10.  Phase II study of central nervous system (CNS)-directed chemotherapy including high-dose chemotherapy with autologous stem cell transplantation for CNS relapse of aggressive lymphomas.

Authors:  Agnieszka Korfel; Thomas Elter; Eckhard Thiel; Matthias Hänel; Robert Möhle; Roland Schroers; Marcel Reiser; Martin Dreyling; Jan Eucker; Christian Scholz; Bernd Metzner; Alexander Röth; Josef Birkmann; Uwe Schlegel; Peter Martus; Gerard Illerhaus; Lars Fischer
Journal:  Haematologica       Date:  2012-12-14       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.